Nicolai Wewer Albrechtsen: Department of Clinical Biochemistry, Copenhagen University Hospital – Bispebjerg, Copenhagen, Denmark
Flávio Adsuara Cadegiani: Corpometria Institute, Brasilia, Brazil
Victor Gault: Ulster University, Northern Ireland, United Kingdom
Submission Status: Open | Submission Deadline: 17 June 2024
BMC Endocrine Disorders is calling for submissions to our Collection on Incretins and incretin-based therapies for obesity, diabetes and other metabolic disorders.
We encourage submission of articles providing (or summarizing) new insights on topics ranging from the elucidation of molecular mechanisms of incretins in homeostasis and disease to the description of novel treatments based on incretin agonists, co-agonists and poly-agonists for obesity, diabetes and other metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Articles describing original research, or studies with translational potential, as well as pre-clinical and clinical investigations are all welcome.
This Collection supports and amplifies research related to SDG 3: Good Health and Well-Being.